NorthStrive Biosciences, Inc., a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB), announced it has submitted 10 new U.S. patent applications aimed at broadening the use of its proprietary EL-22 and EL-32 platforms into animal health and agricultural sectors.
The filings consist of five patent applications related to EL-22 and five corresponding applications for EL-32, covering multiple categories of farmed animals, including livestock, aquaculture species and poultry.
Targeting muscle growth and production efficiency
Two of the patent applications focus on the use of EL-22 and EL-32 as non-feed additive supplements intended to stimulate new muscle formation and increase muscle yield per animal. The company believes this approach could enhance production efficiency without altering traditional feed inputs.
Emissions reduction and livestock health
Additional filings address the potential use of EL-22 and EL-32 to lower gaseous emissions from livestock operations. The company said this could help reduce environmental impact while also potentially lowering the risk of ruminal tympany in cattle.
Aquaculture applications
In aquaculture, NorthStrive has filed patent applications related to promoting muscle growth in farmed fish and other aquatic species. The technology is intended to shorten time to market size and reduce energy costs in production systems.
Separate aquaculture-focused filings aim to address emissions reduction in aquatic environments, with the goal of mitigating eutrophication risks.
Poultry development
The final group of applications covers the use of EL-22 and EL-32 in poultry, with the objective of enhancing muscle development and increasing meat yield per bird within standard growth cycles.
About the companies
NorthStrive Biosciences is a biopharmaceutical company focused on developing and acquiring innovative aesthetic and metabolic therapies. Its lead asset, EL-22, uses an engineered probiotic platform designed to help preserve muscle mass during weight loss treatments, including those involving GLP-1 receptor agonists.
PMGC Holdings Inc. is a diversified holding company that pursues growth through acquisitions, investments and business development across a range of industries.